Glecaprevir

N/A

Report date: 2025/02/06 20:00:06
NME

Base Information

Drug NameGlecaprevir
Drug Alias Name格卡瑞韦Next-generation HCV protease inhibitor - AbbVie/Enanta格来瑞韦GlecaprevirumABT-493 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsFibrosisRenal InsufficiencyHepatic Insufficiency +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsFibrosisRenal InsufficiencyHepatic Insufficiency +[5] 

Other Information

ATC CodeN/A
Related LinksN/A